keyword
MENU ▼
Read by QxMD icon Read
search

Ideglira

keyword
https://www.readbyqxmd.com/read/29797389/management-of-type-2-diabetes-with-fixed-ratio-combination-insulin-degludec-liraglutide-ideglira-versus-basal-bolus-therapy-insulin-glargine-u100-plus-insulin-aspart-a-short-term-cost-effectiveness-analysis-in-the-uk-setting
#1
R S Drummond, Sjp Malkin, M Du Preez, X Y Lee, B Hunt
AIMS: Insulin degludec/liraglutide (IDegLira) is a once-daily, single-injection, fixed-ratio combination of insulin degludec, a basal insulin with a half-life of more than 24 hours, and GLP-1 receptor agonist liraglutide. The present analysis evaluated the cost-effectiveness of IDegLira versus basal-bolus therapy (BBT) with insulin glargine U100 plus up to four times daily insulin aspart for management of type 2 diabetes in the UK. MATERIALS AND METHODS: A Microsoft Excel model was used to evaluate the cost-utility of IDegLira versus BBT over a 1-year time horizon...
May 24, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29796245/the-role-of-basal-insulin-and-glp-1-receptor-agonist-combination-products-in-the-management-of-type-2-diabetes
#2
REVIEW
Taylor R Inman, Erika Plyushko, Nicholas P Austin, Jeremy L Johnson
The prevalence of type 2 diabetes necessitates the development of new treatment options to individualize therapy. Basal insulin has been a standard treatment option for years, while glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have grown in use over the past decade due to glucose-lowering efficacy and weight loss potential. There are two new combination injectable products that have recently been approved combining basal insulins with GLP-1 RAs in single pen-injector devices. United States guidelines recently emphasize the option to use combination injectable therapy with GLP-1 RAs and basal insulin once the basal insulin has been optimally titrated as a second- or third-line agent in addition to metformin without reaching the goal A1c...
May 2018: Therapeutic Advances in Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29686454/safety-and-efficacy-of-insulin-degludec-liraglutide-ideglira-and-insulin-glargine-u100-lixisenatide-iglarlixi-two-novel-co-formulations-of-a-basal-insulin-and-a-glucagon-like-peptide-1-receptor-agonist-in-patients-with-diabetes-not-adequately-controlled-on
#3
Carol H Wysham, Carlos Campos, Davida Kruger
IN BRIEF Novel co-formulations of basal insulin analogs and glucagon-like peptide-1 (GLP-1) receptor agonists have provided new options for patients with type 2 diabetes who are not reaching recommended glycemic targets. The components of currently available co-formulations (insulin degludec/ liraglutide [IDegLira,] and insulin glargine U100/lixisenatide [iGlarLixi]) act synergistically to address multiple pathophysiologic defects while minimizing the side effects associated with either component when used alone...
April 2018: Clinical Diabetes: a Publication of the American Diabetes Association
https://www.readbyqxmd.com/read/29566586/efficacy-and-safety-of-basal-insulin-glp-1-receptor-agonist-used-in-combination-for-type-2-diabetes-management
#4
Delilah McCarty, Alaina Olenik, Bryan P McCarty
PURPOSE: The purpose of this article is to review the efficacy, safety, and place in therapy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (IGlarLixi) in the treatment of type 2 diabetes mellitus. SUMMARY: Type 2 diabetes is a condition affecting nearly 30 million American adults. Management of type 2 diabetes is complex and multifactorial. Using medications targeted at a variety of the physiologic defects known to contribute to the development of type 2 diabetes allows for a patient-specific approach to care...
January 1, 2018: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/29521173/fixed-ratio-combination-therapy-for-type-2-diabetes-the-top-ten-things-you-should-know-about-insulin-and-glucagon-like-peptide-1-receptor-agonist-combinations
#5
Ian Blumer, Jeremy H Pettus, Tricia Santos Cavaiola
Many individuals with type 2 diabetes (T2D) will eventually require insulin therapy to help achieve and maintain adequate glycemic control. However, the use of insulin can be associated with adverse effects such as hypoglycemia and weight gain, and in some patients the addition of insulin to treatment regimens is often still insufficient to achieve target glycemic control. Combining basal insulin with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of patients with T2D has been demonstrated to be effective and well tolerated, while mitigating many of the adverse events associated with giving either of these drug classes alone...
March 20, 2018: Postgraduate Medicine
https://www.readbyqxmd.com/read/29483185/efficacy-and-safety-of-ideglira-versus-basal-bolus-insulin-therapy-in-patients-with-type-2-diabetes-uncontrolled-on-metformin-and-basal-insulin-the-dual-vii-randomized-clinical-trial
#6
Liana K Billings, Ankur Doshi, Didier Gouet, Alejandra Oviedo, Helena W Rodbard, Nikolaos Tentolouris, Randi Grøn, Natalie Halladin, Esteban Jodar
OBJECTIVE: In patients with uncontrolled type 2 diabetes on basal insulin, prandial insulin may be initiated. We assessed the efficacy and safety of initiating insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus basal-bolus insulin. RESEARCH DESIGN AND METHODS: A phase 3b trial examined patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20-50 units/day and metformin, randomized to IDegLira or IGlar U100 and insulin aspart ≤4 times per day...
May 2018: Diabetes Care
https://www.readbyqxmd.com/read/29471700/methodological-concerns-with-the-meta-analysis-comparing-insulin-degludec-liraglutide-and-insulin-glargine-lixisenatide
#7
LETTER
Sarah Eggert, Esther Zimmermann, Kamilla Begtrup
No abstract text is available yet for this article.
March 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29408938/cost-effectiveness-of-liraglutide-versus-lixisenatide-as-add-on-therapies-to-basal-insulin-in-type-2-diabetes
#8
Åsa Ericsson, Divina Glah, Maria Lorenzi, Jeroen P Jansen, Adam Fridhammar
BACKGROUND: We assessed the cost-effectiveness of the glucagon-like peptide 1 receptor agonists liraglutide 1.8 mg and lixisenatide 20 μg (both added to basal insulin) in patients with type 2 diabetes (T2D) in Sweden. METHODS: The Swedish Institute for Health Economics cohort model for T2D was used to compare liraglutide and lixisenatide (both added to basal insulin), with a societal perspective and with comparative treatment effects derived by indirect treatment comparison (ITC)...
2018: PloS One
https://www.readbyqxmd.com/read/29276398/cost-effectiveness-analysis-of-ideglira-versus-basal-bolus-insulin-for-patients-with-type-2-diabetes-in-the-slovak-health-system
#9
Marek Psota, Maria Bucek Psenkova, Natalia Racekova, Antonio Ramirez de Arellano, Tom Vandebrouck, Barnaby Hunt
Aims: To investigate the cost-effectiveness of once-daily insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in patients with type 2 diabetes not meeting glycemic targets on basal insulin from a healthcare payer perspective in Slovakia. Methods: Long-term clinical and economic outcomes for patients receiving IDegLira and basal-bolus therapy were estimated using the IMS CORE Diabetes Model based on a published pooled analysis of patient-level data...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/29205856/use-and-effectiveness-of-a-fixed-ratio-combination-of-insulin-degludec-liraglutide-ideglira-in-a-real-world-population-with-type-2-diabetes-results-from-a-european-multicentre-retrospective-chart-review-study
#10
Hermione Price, Matthias Blüher, Rudolf Prager, Tra-Mi Phan, Brian L Thorsted, Bernd Schultes
AIMS: To describe the real-world use and effectiveness of IDegLira, a fixed-ratio combination of the basal insulin degludec, and the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide. MATERIALS AND METHODS: This European, multicentre, retrospective chart review comprised adults (n = 611) with type 2 diabetes, who started IDegLira ≥6 months before data collection. Clinical characteristics were assessed at baseline (defined as the most recent recording during the 6 months before the first IDegLira prescription) and 3, 6, 9 and 12 months (± 45 days for each time point) after commencing IDegLira, where data were available...
April 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29164973/an-indirect-treatment-comparison-of-the-efficacy-of-insulin-degludec-liraglutide-ideglira-and-insulin-glargine-lixisenatide-iglarlixi-in-patients-with-type-2-diabetes-uncontrolled-on-basal-insulin
#11
Marc Evans, Liana K Billings, Jonas Håkan-Bloch, Ulla Slothuus, Trine J Abrahamsen, Andreas Andersen, Jeroen P Jansen
AIMS: To obtain estimates of the relative treatment effects between insulin degludec/liraglutide (IDegLira) and insulin glargine U100/lixisenatide (iGlarLixi) in patients with type 2 diabetes mellitus (T2DM) uncontrolled on basal insulin therapy. MATERIALS AND METHODS: Data from phase 3 trials providing evidence for estimating the relative efficacy and safety of IDegLira vs iGlarLixi in patients uncontrolled on basal insulin-only regimens were used in this analysis...
April 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29090600/comparison-between-insulin-degludec-liraglutide-treatment-and-insulin-glargine-lixisenatide-treatment-in-type-2-diabetes-a-systematic-review-and-meta-analysis
#12
REVIEW
Xiaoling Cai, Xueying Gao, Wenjia Yang, Linong Ji
AIM: To evaluate the efficacy and adverse effects of IDegLira and IGlarLixi treatment and to perform a comparison between two strategies. METHODS: The registration number is CRD42017053952. Randomized controlled trials of IGlarLixi treatment or IDegLira treatment compared with placebo or active hypoglycemic agents in type 2 diabetes were included. RESULTS: Eight trials were included. The absolute HbA1c change relative to baseline after IGlarLixi treatment was -1...
December 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29063511/cost-effectiveness-of-ideglira-versus-insulin-intensification-regimens-for-the-treatment-of-adults-with-type-2-diabetes-in-the-czech-republic
#13
Milan Kvapil, Martin Prázný, Pavel Holik, Karel Rychna, Barnaby Hunt
INTRODUCTION: The aim of this study was to evaluate the long-term cost-effectiveness of the insulin degludec/liraglutide combination (IDegLira) versus basal insulin intensification strategies for patients with type 2 diabetes mellitus (T2DM) not optimally controlled on basal insulin in the Czech Republic. METHODS: Cost-effectiveness was evaluated using the QuintilesIMS Health CORE Diabetes model, an interactive internet-based model that simulates clinical outcomes and costs for cohorts of patients with diabetes...
December 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28799414/the-clinical-use-of-a-fixed-dose-combination-of-insulin-degludec-and-liraglutide-xultophy-100-3-6-for-the-treatment-of-type-2-diabetes
#14
REVIEW
Kira Harris, Kimberly Lovin Nealy
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of the fixed-dose combination of insulin degludec and the glucagon-like peptide-I receptor agonist (GLP-1 RA), liraglutide (IDegLira) in the treatment of type 2 diabetes mellitus (T2DM). DATA SOURCES: A PubMed and MEDLINE search (1966 to July 2017) of the keywords insulin degludec, liraglutide, and type 2 diabetes mellitus was conducted. References were reviewed to identify additional citations...
January 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28721686/rationale-for-initiation-and-titration-of-the-basal-insulin-glp-1ra-fixed-ratio-combination-products-ideglira-and-iglarlixi-for-the-management-of-type-2-diabetes
#15
REVIEW
Virginia Valentine, Jennifer Goldman, Jay H Shubrook
Type 2 diabetes (T2D) is a progressive disease affecting glucose regulation and a major cause of morbidity and mortality globally. Many patients are not escalated up the treatment ladder appropriately despite failing to achieve glycemic control, with barriers such as fear of hypoglycemia, weight gain, and treatment burden recognized as factors. Exogenous basal insulin is titrated to address control of fasting plasma glucose and may preserve residual β-cell function, thus promoting a greater endogenous prandial insulin response...
August 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28643425/insulin-degludec-liraglutide-ideglira-was-effective-across-a-range-of-dysglycaemia-and-body-mass-index-categories-in-the-dual-v-randomized-trial
#16
Ildiko Lingvay, Stewart Harris, Elmar Jaeckel, Keval Chandarana, Mattis F Ranthe, Esteban Jódar
This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; <30, ≥30 to <35 and ≥35 kg/m2 ) and fasting plasma glucose (FPG; <7.2 and ≥7.2 mmol/L) in patients with type 2 diabetes (T2D) uncontrolled on basal insulin, using post hoc analyses of the DUAL V 26-week trial. With IDegLira, mean HbA1c was reduced across all baseline HbA1c (1...
January 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28643293/-why-is-a-combination-of-basal-insulin-with-a-glp-1-receptor-agonist-useful-in-many-patients-with-type-2-diabetes
#17
Michael Nauck, Birgit Wilhelm
BACKGROUND: In 2015, the combination of basal insulin and GLP-1 receptor agonist (RA) was incorporated into the guideline recommendations for type 2 diabetes as an option for the last escalation step. The two antidiabetics to be injected subcutaneously are complementary regarding their respective main effects and limitations. Basal insulin is predominantly active between meals and in the fasting state, whereas the main action of GLP-1 RA consists in preventing an excessive postprandial blood glucose increase...
June 2017: MMW Fortschritte der Medizin
https://www.readbyqxmd.com/read/28523624/erratum-to-evaluation-of-the-short-term-cost-effectiveness-of-ideglira-versus-continued-up-titration-of-insulin-glargine-u100-in-patients-with-type-2-diabetes-in-the-usa
#18
Barnaby Hunt, Michelle Mocarski, William J Valentine, Jakob Langer
No abstract text is available yet for this article.
June 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28523483/modeling-the-long-term-cost-effectiveness-of-ideglira-in-patients-with-type-2-diabetes-who-are-failing-to-meet-glycemic-targets-on-basal-insulin-alone-in-the-netherlands
#19
Barnaby Hunt, Divina Glah, Maarten van der Vliet
INTRODUCTION: Insulin degludec/liraglutide (IDegLira) is the first basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a single pen injection device, and a once-daily treatment option for patients with type 2 diabetes mellitus (T2DM) who are uncontrolled on basal insulin and require treatment intensification. The objective of this analysis was to evaluate the long-term cost-effectiveness of IDegLira versus basal-bolus therapy (insulin glargine U100 + 3× daily insulin aspart) for patients with T2DM uncontrolled on basal insulin [HbA1c >53 mmol/mol (>7%)] in the Netherlands...
August 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28417535/rates-of-hypoglycaemia-are-lower-in-patients-treated-with-insulin-degludec-liraglutide-ideglira-than-with-ideg-or-insulin-glargine-regardless-of-the-hypoglycaemia-definition-used
#20
Paul Norwood, Roger Chen, Elmar Jaeckel, Ildiko Lingvay, Henrik Jarlov, Lucine Lehmann, Simon Heller
AIMS: To re-analyse, using a series of alternative hypoglycaemia definitions, the data from 2 trials, DUAL I and V, in which the once-daily, fixed ratio combination of insulin degludec/liraglutide (IDegLira) was compared with basal insulin therapy. MATERIAL AND METHODS: Post hoc analyses of the DUAL I (patients uncontrolled on oral antidiabetic drugs) and DUAL V (patients uncontrolled on insulin glargine (IGlar) U100) trials were carried out using different definitions of hypoglycaemia and according to whether treatments were administered in the morning or afternoon...
November 2017: Diabetes, Obesity & Metabolism
keyword
keyword
10134
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"